Acetyl Tetrapeptide-15

CAS 928007-64-1. Not listed in EU Annex II (prohibited) or Annex III (restricted). Registered in CosIng with no concentration limit. No SCCS opinion issued. No CIR safety assessment published. ECHA C&L: 104 of 104 notifications report no GHS hazard classification. Mechanistically sound neurotransmitter-inhibiting peptide (mu-opioid receptor agonism, CGRP suppression) with clinical evidence at 0.0015% active. Primary regulatory limitation is absence of independent public toxicology data — safety substantiation relies on supplier dossier (Lubrizol/Lipotec). Suitable for use in cosmetics at recommended supplier levels (0.2-6% of trade solution), but EU Article 10 Safety Assessments requiring full toxicological dossiers will need direct access to the supplier's confidential data package or commissioned independent testing.

No FDA monograph or restriction applies to Acetyl Tetrapeptide-15. Used as a cosmetic ingredient under FDA general cosmetic regulations. No GRASE classification — not a sunscreen active. No CIR safety assessment has been published for this ingredient. CIR has reviewed structurally related peptides (Tripeptide-1, Hexapeptide-12, Palmitoyl Tetrapeptide-7) but not Acetyl Tetrapeptide-15 specifically. No VCRP-specific data identified in available literature. Trade name Skinasensyl LS 9749 (Lubrizol/Lipotec). Formulators seeking US market safety substantiation should request the supplier's full toxicological dossier.